CA2072891A1 - Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande - Google Patents

Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande

Info

Publication number
CA2072891A1
CA2072891A1 CA2072891A CA2072891A CA2072891A1 CA 2072891 A1 CA2072891 A1 CA 2072891A1 CA 2072891 A CA2072891 A CA 2072891A CA 2072891 A CA2072891 A CA 2072891A CA 2072891 A1 CA2072891 A1 CA 2072891A1
Authority
CA
Canada
Prior art keywords
carboxyl
pseudomonas exotoxin
alterations
fusion proteins
increased cytotoxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2072891A
Other languages
English (en)
Other versions
CA2072891C (fr
Inventor
Ira Pastan
Vijay Chaudhary
David J. Fitzgerald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Ira Pastan
Vijay Chaudhary
David J. Fitzgerald
The United States Of America, Represented By The Secretary, U.S. Departm Ent Of Commerce
United States Of America, Represented By The Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ira Pastan, Vijay Chaudhary, David J. Fitzgerald, The United States Of America, Represented By The Secretary, U.S. Departm Ent Of Commerce, United States Of America, Represented By The Secretary Of The Department Of Health And Human Services filed Critical Ira Pastan
Publication of CA2072891A1 publication Critical patent/CA2072891A1/fr
Application granted granted Critical
Publication of CA2072891C publication Critical patent/CA2072891C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

Exotoxine de Pseudomonas, cytotoxique, recombinée spécifique à une cible. Lesdites toxines sont obtenues par insertion de molécules de reconnaissance spécifiques sur des sites de clonage spécifiques, dans au moins le domaine III au niveau de la terminaison carboxyle de la molécule PE. Diverses modifications de la terminaison carboxyle de la molécule PE augmentant la cytotoxicité, sont présentées.
CA002072891A 1990-01-02 1990-12-27 Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande Expired - Fee Related CA2072891C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45963590A 1990-01-02 1990-01-02
US459,635 1990-01-02
PCT/US1990/007421 WO1991009949A1 (fr) 1990-01-02 1990-12-27 Exotoxine de pseudomonase, cytotoxique, recombinee specifique a une cible

Publications (2)

Publication Number Publication Date
CA2072891A1 true CA2072891A1 (fr) 1991-07-03
CA2072891C CA2072891C (fr) 1999-12-21

Family

ID=23825594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002072891A Expired - Fee Related CA2072891C (fr) 1990-01-02 1990-12-27 Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande

Country Status (5)

Country Link
EP (1) EP0509056A4 (fr)
JP (1) JP2610740B2 (fr)
AU (1) AU644139B2 (fr)
CA (1) CA2072891C (fr)
WO (1) WO1991009949A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
NZ237758A (en) * 1990-04-17 1992-12-23 Shell Int Research (phenylalkyl) triphenylphosphonium salt derivatives and fungicidal compositions
AU646673B2 (en) * 1990-05-11 1994-03-03 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
US20070196366A1 (en) 2003-04-30 2007-08-23 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2016146833A1 (fr) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarqueurs de résistance à la nad(+)-diphtamide adp-ribosyltransférase
EP3184547A1 (fr) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anticorps anti-tpbg et procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity

Also Published As

Publication number Publication date
AU644139B2 (en) 1993-12-02
WO1991009949A1 (fr) 1991-07-11
AU7242491A (en) 1991-07-24
EP0509056A4 (en) 1993-02-17
EP0509056A1 (fr) 1992-10-21
JPH05502032A (ja) 1993-04-15
CA2072891C (fr) 1999-12-21
JP2610740B2 (ja) 1997-05-14

Similar Documents

Publication Publication Date Title
CA2082824A1 (fr) Proteines de fusion multifonctionnelles d'exotoxine de pseudomonas portant des modifications a l'extremite carboxylique et ayant une cytotoxicite accrue
GR3033553T3 (en) Site-specific conjugation of immunoglobulins and detectable labels.
CA2072891A1 (fr) Proteines de fusion d'exotoxine de pseudomonas, avec modifications carboxyliques pour une cytotoxicite plus grande
CA2095797A1 (fr) Arylacetamides
DE69112089T2 (de) Durch die Vernetzung von Holzstoffasern mit Polykarbonsäuren erhaltene elastische, voluminöse Faser.
CA2155185A1 (fr) Reactifs par affinite, totalement synthetiques
EP0361519A3 (fr) Résines phénoxy aqueuses modifiées
CA2075974A1 (fr) Reactifs d'affinite entierement synthetiques
CA2031118A1 (fr) Source lumineuse lineaire
JPS5552311A (en) Mixture of polyurethane and unsaturated polyester resin
EP0823456A4 (fr) Composition de resine polyacetale
DE69106611D1 (de) Motortreibstoffe mit erhöhten Eigenschaften.
DE69100199T2 (de) Brennstoffeinspritzvorrichtung mit Vorverdampfer.
EP0827749A3 (fr) Solution pour dialyse péritonéale
CA2133834A1 (fr) Mode de preparation de proteines modifiees
NZ232564A (en) Pseudomonas exotoxin a, pe40 domain derivatives conjugated to a protein targeting domain
AU591077B2 (en) Prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units
EP0439048A3 (en) Monoclonal antibody recognizing anthracycline glycoside specific epitope and hybridoma secerning said antibody
ITTO911040A1 (it) Serbatorio di carburante per autoveicoli e procedimento per la sua realizzazione.
FR2704823B1 (fr) Chenille pour vehicule presentant des protuberances allongees.
CA2102859A1 (fr) Vecteur d'expression pour une proteine antivirale de phytolacca
ITTO911054A0 (it) Autovettura con carrozzeria trasformabile da coupe' in spider.
DE69001957D1 (de) Polysaccharidfraktion mit einer wirkung gegen hiv.
CA2136239A1 (fr) Leucotriene c4 synthase
ATE181694T1 (de) Im kunststoffspritzverfahren hergestelltes kunstoffbauteil

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed